Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Wendy Stock

Showing results (121-130 of 322) with videos related to

Pageof 33
Sort By:
Cancer|August 27, 2009
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemiaDeborah A Thomas, Hagop M Kantarjian, Wendy Stock, et al.
Leukemia & Lymphoma|January 28, 2012
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemiaEunice S Wang, Karen Yee, Liang Piu Koh, et al.
Blood|March 6, 2002
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasiaSteven M Devine, Ron Hoffman, Amit Verma, et al.
British Journal of Haematology|August 18, 2020
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicinRyan D Cassaday, David I Marks, Daniel J DeAngelo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 7, 2019
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II StudyBrittany Knick Ragon, Olatoyosi Odenike, Maria R Baer, et al.
Leukemia & Lymphoma|May 8, 2020
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study databaseElias Jabbour, Matthias Stelljes, Anjali S Advani, et al.
Leukemia & Lymphoma|November 19, 2016
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL)Kai Lee Yap, Larissa V Furtado, Kazuma Kiyotani, et al.
Pharmacogenetics and Genomics|December 5, 2013
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, et al.
Experimental Hematology & Oncology|January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemiaHongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
Pageof 33

Showing results (121-130 of 322) with videos related to

Sort By:
Pageof 33
Cancer|August 27, 2009
Phase 1 multicenter study of vincristine sulfate liposomes injection and dexamethasone in adults with relapsed or refractory acute lymphoblastic leukemiaDeborah A Thomas, Hagop M Kantarjian, Wendy Stock, et al.
Leukemia & Lymphoma|January 28, 2012
Phase 1 trial of linifanib (ABT-869) in patients with refractory or relapsed acute myeloid leukemiaEunice S Wang, Karen Yee, Liang Piu Koh, et al.
Blood|March 6, 2002
Allogeneic blood cell transplantation following reduced-intensity conditioning is effective therapy for older patients with myelofibrosis with myeloid metaplasiaSteven M Devine, Ron Hoffman, Amit Verma, et al.
British Journal of Haematology|August 18, 2020
Impact of number of cycles on outcomes of patients with relapsed or refractory acute lymphoblastic leukaemia treated with inotuzumab ozogamicinRyan D Cassaday, David I Marks, Daniel J DeAngelo, et al.
Clinical Lymphoma, Myeloma & Leukemia|May 7, 2019
Oral MEK 1/2 Inhibitor Trametinib in Combination With AKT Inhibitor GSK2141795 in Patients With Acute Myeloid Leukemia With RAS Mutations: A Phase II StudyBrittany Knick Ragon, Olatoyosi Odenike, Maria R Baer, et al.
Leukemia & Lymphoma|May 8, 2020
Impact of salvage treatment phase on inotuzumab ozogamicin treatment for relapsed/refractory acute lymphoblastic leukemia: an update from the INO-VATE final study databaseElias Jabbour, Matthias Stelljes, Anjali S Advani, et al.
Leukemia & Lymphoma|November 19, 2016
Diagnostic evaluation of RNA sequencing for the detection of genetic abnormalities associated with Ph-like acute lymphoblastic leukemia (ALL)Kai Lee Yap, Larissa V Furtado, Kazuma Kiyotani, et al.
Pharmacogenetics and Genomics|December 5, 2013
A pharmacogenetic study of aldehyde oxidase I in patients treated with XK469Jacqueline Ramírez, Tae Won Kim, Wanqing Liu, et al.
Experimental Hematology & Oncology|January 19, 2018
WT1 peptide vaccine in Montanide in contrast to poly ICLC, is able to induce WT1-specific immune response with TCR clonal enrichment in myeloid leukemiaHongtao Liu, Yuanyuan Zha, Noura Choudhury, et al.
Cancer|January 31, 2018
Efficacy and safety analysis by age cohort of inotuzumab ozogamicin in patients with relapsed or refractory acute lymphoblastic leukemia enrolled in INO-VATEElias J Jabbour, Daniel J DeAngelo, Matthias Stelljes, et al.
Pageof 33